Skip to main content

4 Result(s)

within J. Hüllein Remove this filter

and

  1. Article

    Open Access

    Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

    Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma associated with MYC translocation. Here, we describe drug response profiling of 42 blood cancer cell lines including 17 BL to 32 drugs targeting key...

    K. Tomska, R. Kurilov, K. S. Lee, J. Hüllein, M. Lukas, L. Sellner… in Scientific Reports (2018)

    Download PDF (5362 KB) View Article

  2. No Access

    Article

    Dissection of CD20 regulation in lymphoma using RNAi

    M Słabicki, K S Lee, A Jethwa, L Sellner, F Sacco, T Walther, J Hüllein… in Leukemia (2016)

  3. No Access

    Article

    p53-dependent non-coding RNA networks in chronic lymphocytic leukemia

    Mutations of the tumor suppressor p53 lead to chemotherapy resistance and a dismal prognosis in chronic lymphocytic leukemia (CLL). Whereas p53 targets are used to identify patient subgroups with impaired p53 ...

    C J Blume, A Hotz-Wagenblatt, J Hüllein, L Sellner, A Jethwa, T Stolz… in Leukemia (2015)

  4. No Access

    Article

    The impact of SF3B1 mutations in CLL on the DNA-damage response

    Mutations or deletions in TP53 or ATM are well-known determinants of poor prognosis in chronic lymphocytic leukemia (CLL), but only account for approximately 40% of chemo-resistant patients. Genome-wide sequencin...

    G D te Raa, I A M Derks, V Navrkalova, A Skowronska, P D Moerland, J van Laar… in Leukemia (2015)